| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Primary Health Care | 10 | 2022 | 351 | 3.950 |
Why?
|
| Poisoning | 20 | 2023 | 42 | 3.100 |
Why?
|
| Drug Overdose | 16 | 2023 | 71 | 2.760 |
Why?
|
| Humans | 256 | 2024 | 89222 | 2.710 |
Why?
|
| Physicians, Primary Care | 4 | 2024 | 105 | 2.230 |
Why?
|
| Substance-Related Disorders | 13 | 2023 | 415 | 1.950 |
Why?
|
| Toxicology | 6 | 2019 | 16 | 1.840 |
Why?
|
| Cannabis | 3 | 2021 | 35 | 1.780 |
Why?
|
| Pyrazoles | 6 | 2017 | 150 | 1.680 |
Why?
|
| Musculoskeletal Diseases | 2 | 2023 | 34 | 1.670 |
Why?
|
| Parkinson Disease | 3 | 2024 | 146 | 1.640 |
Why?
|
| Eye Diseases | 2 | 2024 | 58 | 1.610 |
Why?
|
| Sports Medicine | 2 | 2022 | 58 | 1.550 |
Why?
|
| Antidotes | 8 | 2013 | 23 | 1.500 |
Why?
|
| Private Practice | 3 | 2019 | 11 | 1.410 |
Why?
|
| Emergency Service, Hospital | 21 | 2019 | 521 | 1.360 |
Why?
|
| Carbon Monoxide Poisoning | 15 | 2009 | 18 | 1.350 |
Why?
|
| Communicable Diseases | 4 | 2020 | 63 | 1.320 |
Why?
|
| Lewy Body Disease | 2 | 2022 | 10 | 1.300 |
Why?
|
| Emergencies | 11 | 2022 | 121 | 1.270 |
Why?
|
| Occupational Exposure | 4 | 2022 | 87 | 1.210 |
Why?
|
| Pyridones | 2 | 2017 | 56 | 1.120 |
Why?
|
| Child | 24 | 2024 | 7158 | 1.090 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 186 | 1.050 |
Why?
|
| Acetylcysteine | 3 | 2013 | 70 | 1.040 |
Why?
|
| Methanol | 3 | 2015 | 12 | 1.020 |
Why?
|
| Radiation Injuries | 4 | 2009 | 160 | 1.020 |
Why?
|
| Suicide | 2 | 2024 | 151 | 0.980 |
Why?
|
| Dronabinol | 4 | 2021 | 56 | 0.960 |
Why?
|
| Anemia, Sickle Cell | 3 | 2024 | 144 | 0.960 |
Why?
|
| Muscular Diseases | 2 | 2023 | 64 | 0.950 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2024 | 21 | 0.940 |
Why?
|
| Solvents | 4 | 2015 | 96 | 0.930 |
Why?
|
| Suicide, Attempted | 15 | 2014 | 133 | 0.910 |
Why?
|
| Burns, Chemical | 4 | 2014 | 12 | 0.910 |
Why?
|
| Antiviral Agents | 3 | 2020 | 477 | 0.890 |
Why?
|
| Environmental Exposure | 4 | 2014 | 322 | 0.880 |
Why?
|
| Dermatitis, Atopic | 1 | 2024 | 55 | 0.880 |
Why?
|
| Blood-Borne Pathogens | 1 | 2022 | 4 | 0.860 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2023 | 42 | 0.840 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 41 | 0.840 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 435 | 0.830 |
Why?
|
| Polyneuropathies | 1 | 2022 | 27 | 0.820 |
Why?
|
| Cardiology | 1 | 2023 | 115 | 0.820 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 111 | 0.820 |
Why?
|
| Drug Labeling | 2 | 2013 | 41 | 0.820 |
Why?
|
| Mouth Diseases | 1 | 2022 | 16 | 0.810 |
Why?
|
| Cluster Headache | 1 | 2022 | 2 | 0.810 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2021 | 4 | 0.810 |
Why?
|
| Scleroderma, Systemic | 1 | 2022 | 53 | 0.810 |
Why?
|
| Tendinopathy | 1 | 2022 | 5 | 0.810 |
Why?
|
| Stomatitis | 1 | 2021 | 30 | 0.800 |
Why?
|
| Acetaminophen | 3 | 2013 | 56 | 0.800 |
Why?
|
| Gastrointestinal Tract | 1 | 2024 | 191 | 0.790 |
Why?
|
| Female | 79 | 2024 | 46118 | 0.790 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 249 | 0.790 |
Why?
|
| Male | 82 | 2023 | 42347 | 0.780 |
Why?
|
| Carcinoid Tumor | 1 | 2021 | 45 | 0.780 |
Why?
|
| Adult | 68 | 2023 | 26559 | 0.780 |
Why?
|
| Genetic Therapy | 1 | 2024 | 370 | 0.760 |
Why?
|
| Health Equity | 1 | 2023 | 94 | 0.760 |
Why?
|
| Emergency Medicine | 7 | 2014 | 125 | 0.750 |
Why?
|
| Hypertension | 6 | 2019 | 744 | 0.750 |
Why?
|
| Plant Poisoning | 3 | 2016 | 6 | 0.750 |
Why?
|
| United States | 24 | 2019 | 6975 | 0.740 |
Why?
|
| Renal Insufficiency | 2 | 2011 | 98 | 0.720 |
Why?
|
| Orbital Diseases | 1 | 2020 | 21 | 0.720 |
Why?
|
| Emergency Treatment | 5 | 2014 | 45 | 0.720 |
Why?
|
| Acne Vulgaris | 1 | 2020 | 35 | 0.720 |
Why?
|
| Ethylene Glycol | 5 | 2011 | 6 | 0.720 |
Why?
|
| Surgery, Plastic | 1 | 2020 | 42 | 0.720 |
Why?
|
| Liver Diseases | 2 | 2018 | 242 | 0.710 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 273 | 0.710 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 345 | 0.700 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2019 | 203 | 0.690 |
Why?
|
| Donor Selection | 1 | 2020 | 74 | 0.690 |
Why?
|
| Health Services for Transgender Persons | 1 | 2019 | 2 | 0.690 |
Why?
|
| Vaping | 1 | 2020 | 45 | 0.680 |
Why?
|
| Pancreatitis | 1 | 2020 | 86 | 0.680 |
Why?
|
| Contrast Media | 3 | 2021 | 1090 | 0.680 |
Why?
|
| Hemorrhage | 3 | 2017 | 280 | 0.680 |
Why?
|
| Child Welfare | 1 | 2019 | 38 | 0.670 |
Why?
|
| Medical Marijuana | 1 | 2019 | 7 | 0.670 |
Why?
|
| Miosis | 2 | 2014 | 10 | 0.670 |
Why?
|
| Drainage | 1 | 2020 | 162 | 0.660 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 73 | 0.660 |
Why?
|
| Polonium | 2 | 2009 | 2 | 0.660 |
Why?
|
| Intra-Abdominal Hypertension | 1 | 2019 | 5 | 0.660 |
Why?
|
| Gender Identity | 1 | 2019 | 53 | 0.660 |
Why?
|
| Physicians | 2 | 2018 | 690 | 0.650 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 18 | 0.650 |
Why?
|
| Transsexualism | 1 | 2019 | 34 | 0.640 |
Why?
|
| Adolescent | 24 | 2024 | 9247 | 0.640 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 39 | 0.630 |
Why?
|
| Pleural Effusion | 1 | 2018 | 47 | 0.630 |
Why?
|
| Disease Management | 3 | 2019 | 329 | 0.630 |
Why?
|
| Homicide | 2 | 2009 | 46 | 0.630 |
Why?
|
| Ethylene Glycols | 2 | 2012 | 10 | 0.620 |
Why?
|
| Pressure | 1 | 2019 | 165 | 0.620 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2011 | 66 | 0.620 |
Why?
|
| Lung Diseases | 1 | 2020 | 269 | 0.620 |
Why?
|
| Clonidine | 3 | 2009 | 33 | 0.610 |
Why?
|
| Illinois | 15 | 2020 | 477 | 0.610 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 497 | 0.600 |
Why?
|
| Ephedra | 3 | 2015 | 3 | 0.600 |
Why?
|
| Chemical Warfare Agents | 3 | 2009 | 7 | 0.590 |
Why?
|
| Administration, Oral | 8 | 2022 | 682 | 0.590 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2009 | 33 | 0.590 |
Why?
|
| Hypoglycemic Agents | 3 | 2011 | 349 | 0.590 |
Why?
|
| Metal-on-Metal Joint Prostheses | 2 | 2017 | 3 | 0.590 |
Why?
|
| Tissue Donors | 2 | 2020 | 491 | 0.590 |
Why?
|
| Resuscitation | 3 | 2014 | 109 | 0.590 |
Why?
|
| Referral and Consultation | 3 | 2015 | 341 | 0.580 |
Why?
|
| Transgender Persons | 1 | 2019 | 106 | 0.580 |
Why?
|
| Chelation Therapy | 3 | 2007 | 3 | 0.580 |
Why?
|
| Risk Factors | 15 | 2023 | 5490 | 0.580 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 105 | 0.580 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 763 | 0.580 |
Why?
|
| Meconium | 6 | 1996 | 15 | 0.580 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 312 | 0.570 |
Why?
|
| Hip Prosthesis | 2 | 2017 | 33 | 0.570 |
Why?
|
| Review Literature as Topic | 3 | 2022 | 21 | 0.570 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 122 | 0.570 |
Why?
|
| Teaching | 1 | 2018 | 147 | 0.560 |
Why?
|
| Immunologic Factors | 1 | 2018 | 171 | 0.560 |
Why?
|
| Terrorism | 3 | 2009 | 9 | 0.560 |
Why?
|
| Marijuana Abuse | 1 | 2016 | 26 | 0.560 |
Why?
|
| Organ Transplantation | 1 | 2020 | 276 | 0.560 |
Why?
|
| Factor Xa Inhibitors | 1 | 2016 | 23 | 0.560 |
Why?
|
| Hypertension, Portal | 1 | 2016 | 46 | 0.550 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2019 | 99 | 0.550 |
Why?
|
| Hypothermia | 2 | 2012 | 26 | 0.550 |
Why?
|
| Dexmedetomidine | 1 | 2016 | 13 | 0.550 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.550 |
Why?
|
| Obesity | 1 | 2023 | 970 | 0.540 |
Why?
|
| Analgesics, Opioid | 2 | 2017 | 443 | 0.540 |
Why?
|
| Medication Errors | 5 | 2011 | 39 | 0.540 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 159 | 0.540 |
Why?
|
| Plants, Toxic | 1 | 2016 | 26 | 0.540 |
Why?
|
| Latex Hypersensitivity | 1 | 2015 | 1 | 0.540 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2015 | 7 | 0.530 |
Why?
|
| Patient Care Team | 1 | 2018 | 283 | 0.530 |
Why?
|
| Physician Assistants | 1 | 2016 | 21 | 0.530 |
Why?
|
| Delirium | 1 | 2016 | 72 | 0.520 |
Why?
|
| United States Food and Drug Administration | 3 | 2015 | 135 | 0.520 |
Why?
|
| Nurse Practitioners | 1 | 2016 | 30 | 0.520 |
Why?
|
| Anaphylaxis | 1 | 2015 | 33 | 0.520 |
Why?
|
| Accidents, Home | 2 | 2014 | 16 | 0.520 |
Why?
|
| Metoclopramide | 2 | 2013 | 16 | 0.520 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2015 | 2 | 0.510 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2017 | 101 | 0.510 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2014 | 44 | 0.510 |
Why?
|
| Dopamine Antagonists | 2 | 2013 | 34 | 0.510 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 741 | 0.510 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2013 | 48 | 0.510 |
Why?
|
| Inhalant Abuse | 1 | 2015 | 1 | 0.500 |
Why?
|
| Headache Disorders | 1 | 2015 | 6 | 0.500 |
Why?
|
| Psoriasis | 1 | 2018 | 245 | 0.500 |
Why?
|
| Kidney Diseases | 1 | 2018 | 319 | 0.500 |
Why?
|
| Irritants | 1 | 2014 | 4 | 0.500 |
Why?
|
| Caustics | 1 | 2014 | 4 | 0.490 |
Why?
|
| Urban Health Services | 1 | 2015 | 45 | 0.490 |
Why?
|
| Hemostatic Disorders | 1 | 2014 | 1 | 0.490 |
Why?
|
| Heart Failure | 2 | 2024 | 1183 | 0.490 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2014 | 199 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1176 | 0.480 |
Why?
|
| Spices | 1 | 2014 | 1 | 0.480 |
Why?
|
| Tachycardia | 2 | 2013 | 37 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2013 | 599 | 0.480 |
Why?
|
| Anticonvulsants | 3 | 2008 | 125 | 0.480 |
Why?
|
| Foodborne Diseases | 1 | 2014 | 8 | 0.480 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 76 | 0.480 |
Why?
|
| Creatinine | 3 | 2011 | 293 | 0.480 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 97 | 0.480 |
Why?
|
| Middle Aged | 46 | 2023 | 25929 | 0.470 |
Why?
|
| Substance Abuse Detection | 3 | 2021 | 12 | 0.470 |
Why?
|
| Seeds | 1 | 2014 | 51 | 0.470 |
Why?
|
| Hydrocarbons | 1 | 2014 | 12 | 0.470 |
Why?
|
| Cholinesterases | 1 | 2014 | 17 | 0.470 |
Why?
|
| Phenylcarbamates | 1 | 2014 | 6 | 0.470 |
Why?
|
| Pandemics | 1 | 2020 | 771 | 0.460 |
Why?
|
| Neoplasms | 2 | 2022 | 3037 | 0.460 |
Why?
|
| Bradycardia | 1 | 2014 | 40 | 0.460 |
Why?
|
| Physical Examination | 2 | 2014 | 148 | 0.460 |
Why?
|
| Bioterrorism | 3 | 2009 | 18 | 0.460 |
Why?
|
| Indans | 1 | 2014 | 35 | 0.450 |
Why?
|
| Chronic Pain | 1 | 2016 | 162 | 0.450 |
Why?
|
| Prisoners | 1 | 2014 | 45 | 0.450 |
Why?
|
| Thrombosis | 2 | 2016 | 302 | 0.450 |
Why?
|
| Prosthesis Failure | 2 | 2017 | 116 | 0.450 |
Why?
|
| Gastroparesis | 1 | 2013 | 14 | 0.440 |
Why?
|
| Health Care Costs | 1 | 2015 | 235 | 0.430 |
Why?
|
| Athletes | 2 | 2023 | 52 | 0.430 |
Why?
|
| Cocaine | 7 | 1997 | 76 | 0.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 257 | 0.420 |
Why?
|
| Stomach | 3 | 2009 | 111 | 0.420 |
Why?
|
| Hip | 1 | 2012 | 18 | 0.420 |
Why?
|
| Piperidines | 1 | 2014 | 165 | 0.420 |
Why?
|
| Hearing Loss | 1 | 2013 | 59 | 0.420 |
Why?
|
| Decontamination | 6 | 2014 | 9 | 0.420 |
Why?
|
| Arthralgia | 1 | 2012 | 39 | 0.410 |
Why?
|
| Designer Drugs | 1 | 2012 | 4 | 0.410 |
Why?
|
| Environmental Monitoring | 4 | 2008 | 74 | 0.410 |
Why?
|
| Hip Joint | 1 | 2012 | 54 | 0.410 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 352 | 0.400 |
Why?
|
| Retrospective Studies | 18 | 2021 | 9034 | 0.400 |
Why?
|
| Colitis, Ulcerative | 1 | 2019 | 737 | 0.400 |
Why?
|
| Methemoglobinemia | 3 | 2007 | 10 | 0.400 |
Why?
|
| Insulin, Long-Acting | 1 | 2011 | 5 | 0.400 |
Why?
|
| Insulin Lispro | 1 | 2011 | 3 | 0.400 |
Why?
|
| Asthma | 2 | 2019 | 977 | 0.390 |
Why?
|
| 2-Propanol | 1 | 2011 | 2 | 0.390 |
Why?
|
| Ethics, Medical | 1 | 2014 | 307 | 0.390 |
Why?
|
| Amphotericin B | 1 | 2011 | 34 | 0.380 |
Why?
|
| Colonic Diseases | 1 | 2011 | 61 | 0.380 |
Why?
|
| Child, Preschool | 14 | 2024 | 3724 | 0.380 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2015 | 60 | 0.380 |
Why?
|
| Medical Order Entry Systems | 1 | 2011 | 25 | 0.370 |
Why?
|
| Isoxazoles | 1 | 2011 | 77 | 0.370 |
Why?
|
| Methamphetamine | 1 | 2012 | 85 | 0.370 |
Why?
|
| Poison Control Centers | 5 | 2014 | 18 | 0.360 |
Why?
|
| Heart Arrest | 4 | 2002 | 279 | 0.360 |
Why?
|
| Drug Carriers | 1 | 2011 | 82 | 0.360 |
Why?
|
| Carbon Monoxide | 6 | 2000 | 93 | 0.360 |
Why?
|
| Risk Assessment | 5 | 2020 | 2301 | 0.360 |
Why?
|
| Critical Care | 6 | 2014 | 380 | 0.360 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2010 | 17 | 0.360 |
Why?
|
| Antifungal Agents | 1 | 2011 | 120 | 0.360 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 2412 | 0.350 |
Why?
|
| Ammonium Chloride | 1 | 2009 | 21 | 0.350 |
Why?
|
| Plasma Exchange | 1 | 2010 | 30 | 0.350 |
Why?
|
| Cervical Vertebrae | 2 | 2009 | 81 | 0.350 |
Why?
|
| Arsenic Poisoning | 2 | 2007 | 103 | 0.350 |
Why?
|
| Household Products | 1 | 2009 | 9 | 0.350 |
Why?
|
| Dystonia | 2 | 2008 | 29 | 0.350 |
Why?
|
| Neck Pain | 1 | 2009 | 18 | 0.350 |
Why?
|
| Radioactive Hazard Release | 2 | 2007 | 8 | 0.350 |
Why?
|
| Treatment Outcome | 13 | 2017 | 8227 | 0.350 |
Why?
|
| Muscle Weakness | 1 | 2010 | 60 | 0.340 |
Why?
|
| Carboxyhemoglobin | 10 | 1990 | 16 | 0.340 |
Why?
|
| Food Additives | 2 | 2000 | 2 | 0.340 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2009 | 6 | 0.340 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 373 | 0.340 |
Why?
|
| Immunoglobulins | 1 | 2010 | 144 | 0.340 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 643 | 0.340 |
Why?
|
| Syncope | 1 | 2009 | 34 | 0.330 |
Why?
|
| Dry Ice | 1 | 2009 | 2 | 0.330 |
Why?
|
| Confined Spaces | 1 | 2009 | 2 | 0.330 |
Why?
|
| Renal Dialysis | 4 | 2007 | 335 | 0.330 |
Why?
|
| Asphyxia | 1 | 2009 | 11 | 0.330 |
Why?
|
| Esophagus | 1 | 2009 | 106 | 0.330 |
Why?
|
| Chemical Terrorism | 1 | 2009 | 2 | 0.330 |
Why?
|
| Biological Warfare Agents | 1 | 2009 | 3 | 0.330 |
Why?
|
| Insecticides | 2 | 2008 | 27 | 0.330 |
Why?
|
| Respiratory System | 1 | 2009 | 116 | 0.330 |
Why?
|
| Lead Poisoning | 3 | 2004 | 10 | 0.330 |
Why?
|
| Cosmetic Techniques | 1 | 2009 | 28 | 0.320 |
Why?
|
| Myocarditis | 2 | 2000 | 51 | 0.320 |
Why?
|
| Clinical Competence | 1 | 2014 | 782 | 0.320 |
Why?
|
| Pyrethrins | 1 | 2008 | 10 | 0.320 |
Why?
|
| Bronchiectasis | 1 | 2008 | 14 | 0.320 |
Why?
|
| Stuttering | 1 | 2008 | 22 | 0.320 |
Why?
|
| Gulf War | 1 | 2008 | 1 | 0.320 |
Why?
|
| Nipecotic Acids | 1 | 2008 | 5 | 0.320 |
Why?
|
| Foscarnet | 1 | 2008 | 12 | 0.310 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 356 | 0.310 |
Why?
|
| Acidosis | 2 | 2013 | 55 | 0.310 |
Why?
|
| Mental Disorders | 2 | 2009 | 413 | 0.310 |
Why?
|
| Status Epilepticus | 1 | 2008 | 35 | 0.300 |
Why?
|
| Dapsone | 1 | 2007 | 10 | 0.300 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2009 | 107 | 0.300 |
Why?
|
| Charcoal | 4 | 2005 | 13 | 0.300 |
Why?
|
| Dermatology | 2 | 2018 | 40 | 0.300 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2008 | 78 | 0.300 |
Why?
|
| Young Adult | 6 | 2023 | 6301 | 0.300 |
Why?
|
| Aged | 23 | 2023 | 19128 | 0.290 |
Why?
|
| Cross Infection | 1 | 2008 | 147 | 0.290 |
Why?
|
| Mercury Poisoning | 1 | 2007 | 1 | 0.290 |
Why?
|
| Mercuric Chloride | 1 | 2007 | 9 | 0.290 |
Why?
|
| Breast Feeding | 1 | 2008 | 102 | 0.290 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 433 | 0.280 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2280 | 0.280 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 386 | 0.280 |
Why?
|
| Oxides | 1 | 2007 | 43 | 0.280 |
Why?
|
| DEET | 2 | 1999 | 6 | 0.280 |
Why?
|
| Military Personnel | 1 | 2008 | 91 | 0.280 |
Why?
|
| Anion Exchange Resins | 1 | 2006 | 1 | 0.280 |
Why?
|
| Pfiesteria piscicida | 1 | 2006 | 1 | 0.280 |
Why?
|
| Cholestyramine Resin | 1 | 2006 | 3 | 0.280 |
Why?
|
| Protozoan Infections | 1 | 2006 | 3 | 0.270 |
Why?
|
| Acute Disease | 8 | 2014 | 841 | 0.270 |
Why?
|
| Fatal Outcome | 3 | 2015 | 299 | 0.270 |
Why?
|
| Behavior, Addictive | 1 | 2008 | 134 | 0.270 |
Why?
|
| History, 20th Century | 3 | 2020 | 310 | 0.270 |
Why?
|
| Antipsychotic Agents | 2 | 2011 | 131 | 0.270 |
Why?
|
| Pediatrics | 2 | 2022 | 352 | 0.270 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 7 | 2008 | 42 | 0.270 |
Why?
|
| Ischemia | 2 | 2006 | 251 | 0.260 |
Why?
|
| Protective Agents | 1 | 2006 | 33 | 0.260 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 271 | 0.260 |
Why?
|
| Leukemia | 1 | 2008 | 323 | 0.260 |
Why?
|
| Time Factors | 10 | 2020 | 5336 | 0.260 |
Why?
|
| Cobalt | 2 | 2017 | 30 | 0.260 |
Why?
|
| Chromium | 2 | 2017 | 17 | 0.260 |
Why?
|
| Administration, Topical | 5 | 2018 | 96 | 0.250 |
Why?
|
| Diphenhydramine | 4 | 2008 | 17 | 0.250 |
Why?
|
| Diarrhea | 1 | 2006 | 182 | 0.250 |
Why?
|
| Infant, Newborn | 12 | 2009 | 2481 | 0.250 |
Why?
|
| Alkalosis, Respiratory | 1 | 2004 | 4 | 0.240 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2004 | 18 | 0.240 |
Why?
|
| Petroleum | 2 | 2002 | 13 | 0.240 |
Why?
|
| Hypnotics and Sedatives | 3 | 2016 | 131 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 711 | 0.230 |
Why?
|
| Emergency Medical Services | 2 | 2007 | 238 | 0.230 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2001 | 21 | 0.230 |
Why?
|
| Hospitalization | 1 | 2009 | 877 | 0.230 |
Why?
|
| Nuclear Warfare | 1 | 2003 | 4 | 0.230 |
Why?
|
| Therapeutic Irrigation | 4 | 2007 | 61 | 0.230 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2023 | 16 | 0.230 |
Why?
|
| Methylene Blue | 1 | 2003 | 18 | 0.220 |
Why?
|
| HIV Infections | 2 | 2014 | 838 | 0.220 |
Why?
|
| Occupational Diseases | 2 | 2003 | 55 | 0.220 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 1719 | 0.220 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2003 | 42 | 0.220 |
Why?
|
| Blood Glucose | 4 | 2021 | 836 | 0.220 |
Why?
|
| Leukemoid Reaction | 1 | 2002 | 5 | 0.210 |
Why?
|
| Sodium Cyanide | 1 | 2002 | 6 | 0.210 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2023 | 52 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 1940 | 0.210 |
Why?
|
| Infant | 14 | 2003 | 3152 | 0.210 |
Why?
|
| Sorbitol | 2 | 2001 | 8 | 0.210 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2016 | 46 | 0.210 |
Why?
|
| Autopsy | 1 | 2003 | 122 | 0.210 |
Why?
|
| Sympathomimetics | 2 | 2000 | 12 | 0.210 |
Why?
|
| Cathartics | 2 | 2001 | 27 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 4 | 2003 | 91 | 0.210 |
Why?
|
| Metformin | 1 | 2004 | 124 | 0.210 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 434 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2010 | 1838 | 0.210 |
Why?
|
| Epinephrine | 4 | 1999 | 86 | 0.210 |
Why?
|
| Age Factors | 3 | 2019 | 1868 | 0.200 |
Why?
|
| Toluene | 1 | 2002 | 5 | 0.200 |
Why?
|
| Benzene | 1 | 2002 | 8 | 0.200 |
Why?
|
| Hospital Units | 4 | 1995 | 30 | 0.200 |
Why?
|
| Influenza, Human | 2 | 2020 | 337 | 0.200 |
Why?
|
| Mianserin | 1 | 2001 | 4 | 0.200 |
Why?
|
| Penile Induration | 1 | 2002 | 7 | 0.200 |
Why?
|
| Vomiting | 2 | 2021 | 194 | 0.200 |
Why?
|
| Pregnancy | 7 | 2018 | 3015 | 0.200 |
Why?
|
| Risperidone | 1 | 2001 | 23 | 0.200 |
Why?
|
| Internal Medicine | 2 | 2018 | 355 | 0.200 |
Why?
|
| Cause of Death | 2 | 2020 | 266 | 0.190 |
Why?
|
| Acidosis, Respiratory | 1 | 2001 | 7 | 0.190 |
Why?
|
| Liver | 2 | 2006 | 1206 | 0.190 |
Why?
|
| Acetic Acid | 1 | 2001 | 8 | 0.190 |
Why?
|
| History, 21st Century | 2 | 2020 | 179 | 0.190 |
Why?
|
| Incidence | 3 | 2011 | 1593 | 0.190 |
Why?
|
| Erectile Dysfunction | 1 | 2002 | 75 | 0.190 |
Why?
|
| Urban Health | 1 | 2001 | 56 | 0.180 |
Why?
|
| Wisconsin | 1 | 2020 | 41 | 0.180 |
Why?
|
| Diagnosis, Differential | 6 | 2011 | 1596 | 0.180 |
Why?
|
| Mass Vaccination | 1 | 2020 | 9 | 0.180 |
Why?
|
| Dermatitis, Occupational | 1 | 2000 | 2 | 0.180 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 2000 | 4 | 0.180 |
Why?
|
| Hallucinogens | 2 | 2014 | 77 | 0.180 |
Why?
|
| Ibuprofen | 1 | 2000 | 28 | 0.180 |
Why?
|
| Health Personnel | 1 | 2022 | 215 | 0.180 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 645 | 0.180 |
Why?
|
| Insect Repellents | 1 | 1999 | 3 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 242 | 0.170 |
Why?
|
| Gentamicins | 1 | 1999 | 20 | 0.170 |
Why?
|
| Rhabdomyolysis | 3 | 2003 | 28 | 0.170 |
Why?
|
| Treatment Failure | 1 | 2020 | 287 | 0.170 |
Why?
|
| Primidone | 1 | 1999 | 2 | 0.170 |
Why?
|
| Back Pain | 1 | 1999 | 42 | 0.170 |
Why?
|
| Chicago | 7 | 2015 | 1424 | 0.170 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 2013 | 23 | 0.170 |
Why?
|
| Fentanyl | 1 | 1999 | 67 | 0.170 |
Why?
|
| Current Procedural Terminology | 1 | 2019 | 12 | 0.170 |
Why?
|
| Succimer | 3 | 2007 | 3 | 0.160 |
Why?
|
| Legislation, Medical | 1 | 1999 | 9 | 0.160 |
Why?
|
| Russia | 2 | 2009 | 26 | 0.160 |
Why?
|
| Alkaloids | 1 | 1999 | 46 | 0.160 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 42 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2019 | 45 | 0.160 |
Why?
|
| Hazardous Substances | 2 | 2014 | 7 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 1999 | 37 | 0.160 |
Why?
|
| Cross Reactions | 2 | 2015 | 109 | 0.160 |
Why?
|
| Genital Diseases, Female | 1 | 2018 | 24 | 0.160 |
Why?
|
| Cocaine-Related Disorders | 1 | 1999 | 36 | 0.160 |
Why?
|
| Air Pollution, Indoor | 2 | 1998 | 64 | 0.160 |
Why?
|
| Graft Survival | 2 | 2020 | 900 | 0.160 |
Why?
|
| Patient Admission | 6 | 2009 | 114 | 0.160 |
Why?
|
| New Orleans | 1 | 2018 | 6 | 0.160 |
Why?
|
| General Practice | 1 | 2018 | 9 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 151 | 0.160 |
Why?
|
| Registries | 2 | 2020 | 781 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1999 | 105 | 0.160 |
Why?
|
| Cysteine | 1 | 1999 | 136 | 0.160 |
Why?
|
| Brain Diseases | 1 | 1999 | 186 | 0.160 |
Why?
|
| Professional Role | 1 | 2018 | 41 | 0.160 |
Why?
|
| Urologic Diseases | 1 | 2018 | 44 | 0.150 |
Why?
|
| Cerebrovascular Disorders | 1 | 1999 | 143 | 0.150 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2013 | 23 | 0.150 |
Why?
|
| Lightning Injuries | 1 | 1997 | 2 | 0.150 |
Why?
|
| Phencyclidine | 2 | 1988 | 7 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2019 | 221 | 0.150 |
Why?
|
| Geriatrics | 1 | 2018 | 66 | 0.150 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2017 | 13 | 0.150 |
Why?
|
| Prognosis | 6 | 2010 | 3779 | 0.150 |
Why?
|
| Phenytoin | 2 | 1988 | 15 | 0.150 |
Why?
|
| Neurology | 1 | 2018 | 74 | 0.150 |
Why?
|
| Crack Cocaine | 1 | 1997 | 3 | 0.140 |
Why?
|
| Flumazenil | 2 | 1997 | 8 | 0.140 |
Why?
|
| Disaster Planning | 3 | 2007 | 24 | 0.140 |
Why?
|
| Epidemics | 1 | 2017 | 34 | 0.140 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 114 | 0.140 |
Why?
|
| Vernix Caseosa | 1 | 1996 | 1 | 0.140 |
Why?
|
| Fever | 1 | 1997 | 128 | 0.140 |
Why?
|
| Half-Life | 1 | 2016 | 97 | 0.140 |
Why?
|
| Hair | 1 | 1997 | 56 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2023 | 4281 | 0.140 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 28 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 57 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 153 | 0.140 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 784 | 0.140 |
Why?
|
| Benzodiazepines | 3 | 2008 | 67 | 0.140 |
Why?
|
| Education, Continuing | 2 | 2007 | 11 | 0.140 |
Why?
|
| Insulin | 1 | 2021 | 1146 | 0.140 |
Why?
|
| Atlases as Topic | 1 | 2016 | 8 | 0.130 |
Why?
|
| Child Abuse | 1 | 1997 | 83 | 0.130 |
Why?
|
| Gastroenterology | 1 | 2018 | 144 | 0.130 |
Why?
|
| Epilepsy | 1 | 2000 | 423 | 0.130 |
Why?
|
| Dimercaprol | 2 | 2007 | 6 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2011 | 119 | 0.130 |
Why?
|
| Hydrocodone | 1 | 1995 | 7 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2013 | 6799 | 0.130 |
Why?
|
| Burns | 1 | 1997 | 141 | 0.130 |
Why?
|
| Forensic Toxicology | 1 | 2015 | 1 | 0.130 |
Why?
|
| Paint | 1 | 2015 | 4 | 0.130 |
Why?
|
| Medicare | 1 | 2019 | 424 | 0.130 |
Why?
|
| Disability Evaluation | 2 | 2010 | 140 | 0.130 |
Why?
|
| Organic Chemicals | 1 | 2015 | 34 | 0.120 |
Why?
|
| Movement Disorders | 2 | 2013 | 44 | 0.120 |
Why?
|
| Medical History Taking | 2 | 2014 | 82 | 0.120 |
Why?
|
| Narcotics | 2 | 2011 | 70 | 0.120 |
Why?
|
| Circadian Rhythm | 3 | 1994 | 305 | 0.120 |
Why?
|
| Acyclovir | 1 | 1995 | 108 | 0.120 |
Why?
|
| Coma | 1 | 2015 | 47 | 0.120 |
Why?
|
| Intubation, Intratracheal | 3 | 2000 | 148 | 0.120 |
Why?
|
| Herpes Zoster | 1 | 1995 | 79 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 60 | 0.120 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2014 | 18 | 0.120 |
Why?
|
| Food Hypersensitivity | 1 | 2015 | 71 | 0.120 |
Why?
|
| London | 2 | 2017 | 16 | 0.120 |
Why?
|
| Prisons | 1 | 2014 | 12 | 0.120 |
Why?
|
| Seizures | 3 | 1997 | 306 | 0.120 |
Why?
|
| Rivastigmine | 1 | 2014 | 4 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2008 | 3661 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2015 | 147 | 0.120 |
Why?
|
| Hypokalemia | 1 | 1994 | 23 | 0.120 |
Why?
|
| Physician's Role | 1 | 1996 | 177 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 1994 | 69 | 0.110 |
Why?
|
| Child Behavior | 1 | 2014 | 47 | 0.110 |
Why?
|
| Albuterol | 1 | 1994 | 35 | 0.110 |
Why?
|
| Eye | 1 | 2014 | 111 | 0.110 |
Why?
|
| Occupational Health | 2 | 2007 | 36 | 0.110 |
Why?
|
| Domperidone | 1 | 2013 | 8 | 0.110 |
Why?
|
| Pharmacovigilance | 1 | 2013 | 3 | 0.110 |
Why?
|
| Crotalid Venoms | 1 | 1993 | 2 | 0.110 |
Why?
|
| Snake Bites | 1 | 1993 | 2 | 0.110 |
Why?
|
| Antivenins | 1 | 1993 | 3 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2015 | 187 | 0.110 |
Why?
|
| Basidiomycota | 1 | 1993 | 10 | 0.110 |
Why?
|
| Paraplegia | 1 | 1993 | 17 | 0.110 |
Why?
|
| Streptococcus pyogenes | 1 | 1993 | 35 | 0.110 |
Why?
|
| Heavy Metal Poisoning | 1 | 2013 | 1 | 0.110 |
Why?
|
| Emergency Services, Psychiatric | 2 | 2007 | 12 | 0.110 |
Why?
|
| Virginia | 1 | 2013 | 16 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2007 | 260 | 0.110 |
Why?
|
| Adolescent Behavior | 1 | 2014 | 109 | 0.110 |
Why?
|
| Respiration, Artificial | 2 | 2010 | 352 | 0.110 |
Why?
|
| Metals, Heavy | 1 | 2013 | 15 | 0.110 |
Why?
|
| Liability, Legal | 1 | 2013 | 32 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 56 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 2 | 1992 | 9 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2014 | 127 | 0.110 |
Why?
|
| Fluorescence Polarization Immunoassay | 4 | 1996 | 4 | 0.100 |
Why?
|
| Immunotherapy | 2 | 1991 | 678 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 1993 | 107 | 0.100 |
Why?
|
| Terpenes | 1 | 1992 | 17 | 0.100 |
Why?
|
| Creatine Kinase | 2 | 1989 | 52 | 0.100 |
Why?
|
| Immersion Foot | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2013 | 2866 | 0.100 |
Why?
|
| Shock, Septic | 1 | 1993 | 105 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2014 | 172 | 0.100 |
Why?
|
| Blood Pressure | 4 | 1991 | 900 | 0.100 |
Why?
|
| Frostbite | 1 | 2012 | 8 | 0.100 |
Why?
|
| Forecasting | 1 | 2013 | 306 | 0.100 |
Why?
|
| Brain | 1 | 2022 | 2281 | 0.100 |
Why?
|
| Insulin Glargine | 1 | 2011 | 9 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 1994 | 463 | 0.100 |
Why?
|
| Droperidol | 1 | 2011 | 3 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 1243 | 0.100 |
Why?
|
| Foreign Bodies | 2 | 2002 | 66 | 0.100 |
Why?
|
| Labetalol | 1 | 1991 | 6 | 0.100 |
Why?
|
| Nifedipine | 2 | 1991 | 25 | 0.100 |
Why?
|
| Arsanilic Acid | 1 | 1991 | 1 | 0.100 |
Why?
|
| September 11 Terrorist Attacks | 2 | 2008 | 2 | 0.100 |
Why?
|
| Periodicity | 1 | 1992 | 119 | 0.090 |
Why?
|
| Chelating Agents | 2 | 2004 | 69 | 0.090 |
Why?
|
| Hypothermia, Induced | 1 | 2012 | 82 | 0.090 |
Why?
|
| Methylene Chloride | 1 | 1990 | 2 | 0.090 |
Why?
|
| Prescription Drugs | 1 | 2011 | 36 | 0.090 |
Why?
|
| Methadone | 1 | 2011 | 46 | 0.090 |
Why?
|
| Liposomes | 1 | 2011 | 93 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 1995 | 414 | 0.090 |
Why?
|
| Bilirubin | 1 | 2011 | 129 | 0.090 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2007 | 17 | 0.090 |
Why?
|
| Regional Medical Programs | 1 | 1990 | 5 | 0.090 |
Why?
|
| Electrocardiography | 6 | 2001 | 494 | 0.090 |
Why?
|
| Schools, Medical | 1 | 1992 | 134 | 0.090 |
Why?
|
| Nalbuphine | 1 | 1990 | 3 | 0.090 |
Why?
|
| Morphinans | 1 | 1990 | 4 | 0.090 |
Why?
|
| Meperidine | 1 | 1990 | 13 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 1992 | 162 | 0.090 |
Why?
|
| Epiglottitis | 1 | 1990 | 1 | 0.090 |
Why?
|
| Laryngitis | 1 | 1990 | 2 | 0.090 |
Why?
|
| Anthrax | 2 | 2008 | 30 | 0.090 |
Why?
|
| Intestines | 2 | 2005 | 416 | 0.090 |
Why?
|
| Parotitis | 1 | 1990 | 6 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 1991 | 157 | 0.090 |
Why?
|
| Liver Abscess | 1 | 1990 | 12 | 0.090 |
Why?
|
| Trauma Centers | 2 | 1990 | 144 | 0.090 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 330 | 0.090 |
Why?
|
| Muscle Relaxants, Central | 1 | 1990 | 10 | 0.090 |
Why?
|
| Nitroglycerin | 1 | 1990 | 23 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2015 | 749 | 0.090 |
Why?
|
| Ethanol | 1 | 1992 | 250 | 0.090 |
Why?
|
| Gastroscopy | 1 | 2009 | 25 | 0.090 |
Why?
|
| Survival Rate | 2 | 2010 | 1900 | 0.090 |
Why?
|
| Neurosurgery | 1 | 2011 | 99 | 0.090 |
Why?
|
| Digoxin | 2 | 1990 | 21 | 0.090 |
Why?
|
| Muscles | 1 | 1990 | 193 | 0.090 |
Why?
|
| Electromyography | 1 | 2010 | 193 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1534 | 0.080 |
Why?
|
| Administration, Inhalation | 2 | 2002 | 190 | 0.080 |
Why?
|
| Causality | 1 | 2009 | 80 | 0.080 |
Why?
|
| Tissue and Organ Procurement | 1 | 1994 | 346 | 0.080 |
Why?
|
| Esophagoscopy | 1 | 2009 | 90 | 0.080 |
Why?
|
| Population Surveillance | 2 | 2001 | 216 | 0.080 |
Why?
|
| Automobiles | 1 | 2009 | 13 | 0.080 |
Why?
|
| Weapons of Mass Destruction | 1 | 2009 | 2 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 219 | 0.080 |
Why?
|
| Polyarteritis Nodosa | 1 | 1988 | 7 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2013 | 447 | 0.080 |
Why?
|
| Mesoridazine | 1 | 1988 | 1 | 0.080 |
Why?
|
| Software | 1 | 1993 | 665 | 0.080 |
Why?
|
| Education, Medical | 1 | 1992 | 243 | 0.080 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2008 | 7 | 0.080 |
Why?
|
| Lice Infestations | 1 | 2008 | 3 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1990 | 83 | 0.080 |
Why?
|
| Motor Skills Disorders | 1 | 2008 | 15 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 60 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2008 | 29 | 0.080 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2008 | 27 | 0.080 |
Why?
|
| Heart Diseases | 2 | 1993 | 298 | 0.080 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1988 | 3 | 0.080 |
Why?
|
| Abdomen | 1 | 1988 | 122 | 0.080 |
Why?
|
| Gestational Age | 1 | 2009 | 325 | 0.080 |
Why?
|
| Cholinergic Antagonists | 1 | 2008 | 27 | 0.080 |
Why?
|
| Milk, Human | 1 | 2008 | 45 | 0.080 |
Why?
|
| Military Medicine | 1 | 2008 | 20 | 0.080 |
Why?
|
| Botulinum Toxins | 2 | 2005 | 17 | 0.080 |
Why?
|
| Bronchoscopy | 1 | 2009 | 159 | 0.080 |
Why?
|
| Skin Absorption | 2 | 2004 | 4 | 0.080 |
Why?
|
| Colon | 1 | 2011 | 509 | 0.080 |
Why?
|
| Health Facility Closure | 1 | 1988 | 7 | 0.080 |
Why?
|
| Europe | 1 | 2008 | 321 | 0.080 |
Why?
|
| Viremia | 1 | 2008 | 49 | 0.080 |
Why?
|
| Potassium | 2 | 1988 | 253 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 76 | 0.080 |
Why?
|
| Total Quality Management | 1 | 2007 | 33 | 0.080 |
Why?
|
| Sodium Bicarbonate | 1 | 2007 | 9 | 0.080 |
Why?
|
| Bacillus anthracis | 1 | 2008 | 73 | 0.070 |
Why?
|
| Propofol | 1 | 2008 | 92 | 0.070 |
Why?
|
| Health Facilities | 1 | 1988 | 36 | 0.070 |
Why?
|
| Epilepsy, Generalized | 1 | 2008 | 40 | 0.070 |
Why?
|
| Powders | 1 | 2008 | 77 | 0.070 |
Why?
|
| Antibodies | 2 | 1991 | 353 | 0.070 |
Why?
|
| Sodium Chloride | 1 | 2007 | 88 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2008 | 115 | 0.070 |
Why?
|
| Dizziness | 3 | 2001 | 26 | 0.070 |
Why?
|
| Benchmarking | 1 | 2007 | 79 | 0.070 |
Why?
|
| Global Health | 1 | 2008 | 186 | 0.070 |
Why?
|
| Ciguatera Poisoning | 1 | 1987 | 1 | 0.070 |
Why?
|
| Marine Toxins | 1 | 1987 | 7 | 0.070 |
Why?
|
| Amitriptyline | 1 | 1987 | 11 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 1994 | 850 | 0.070 |
Why?
|
| Chorea | 1 | 2006 | 12 | 0.070 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2006 | 19 | 0.070 |
Why?
|
| Arsenicals | 1 | 2007 | 48 | 0.070 |
Why?
|
| Atropine | 1 | 1986 | 60 | 0.070 |
Why?
|
| Equipment Failure | 2 | 1998 | 121 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2002 | 899 | 0.070 |
Why?
|
| Amphetamines | 2 | 1997 | 18 | 0.070 |
Why?
|
| Antisocial Personality Disorder | 1 | 2007 | 92 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 1986 | 32 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 1994 | 1177 | 0.070 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1986 | 19 | 0.070 |
Why?
|
| Anxiety Disorders | 1 | 2007 | 152 | 0.070 |
Why?
|
| Pneumonia | 2 | 1990 | 182 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 144 | 0.070 |
Why?
|
| Radiation Dosage | 2 | 2003 | 226 | 0.070 |
Why?
|
| Leukocytosis | 1 | 1985 | 16 | 0.060 |
Why?
|
| Hemoglobins | 1 | 1986 | 192 | 0.060 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2005 | 22 | 0.060 |
Why?
|
| Theophylline | 1 | 1985 | 33 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2006 | 111 | 0.060 |
Why?
|
| Naloxone | 1 | 2005 | 64 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2005 | 75 | 0.060 |
Why?
|
| Animals | 7 | 2009 | 27338 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1488 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 358 | 0.060 |
Why?
|
| Ceramics | 1 | 2004 | 1 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1986 | 210 | 0.060 |
Why?
|
| Pica | 1 | 2004 | 14 | 0.060 |
Why?
|
| Edetic Acid | 1 | 2004 | 42 | 0.060 |
Why?
|
| Seasons | 5 | 2001 | 237 | 0.060 |
Why?
|
| Jurisprudence | 1 | 2004 | 25 | 0.060 |
Why?
|
| Arum | 1 | 2003 | 2 | 0.060 |
Why?
|
| Laryngeal Edema | 1 | 2003 | 7 | 0.060 |
Why?
|
| Diagnosis | 2 | 1995 | 18 | 0.060 |
Why?
|
| Aggression | 1 | 1988 | 322 | 0.060 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2004 | 28 | 0.060 |
Why?
|
| Facial Nerve Diseases | 1 | 2003 | 3 | 0.060 |
Why?
|
| Inhalation Exposure | 1 | 2004 | 31 | 0.060 |
Why?
|
| Nuclear Reactors | 1 | 2003 | 7 | 0.060 |
Why?
|
| Narcotic Antagonists | 1 | 2005 | 157 | 0.060 |
Why?
|
| Postmortem Changes | 1 | 2003 | 8 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2003 | 121 | 0.050 |
Why?
|
| Pharmacokinetics | 1 | 2003 | 10 | 0.050 |
Why?
|
| Intestinal Absorption | 1 | 2003 | 124 | 0.050 |
Why?
|
| Soman | 1 | 2002 | 1 | 0.050 |
Why?
|
| Organophosphate Poisoning | 1 | 2002 | 2 | 0.050 |
Why?
|
| Sarin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 40 | 0.050 |
Why?
|
| Organophosphates | 1 | 2002 | 6 | 0.050 |
Why?
|
| Thiosulfates | 1 | 2002 | 3 | 0.050 |
Why?
|
| Organothiophosphorus Compounds | 1 | 2002 | 17 | 0.050 |
Why?
|
| Airway Obstruction | 1 | 2003 | 110 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2003 | 293 | 0.050 |
Why?
|
| Hospitals, University | 3 | 2011 | 196 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2003 | 195 | 0.050 |
Why?
|
| Trichloroethylene | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemical Warfare | 1 | 2002 | 2 | 0.050 |
Why?
|
| Biological Warfare | 1 | 2002 | 6 | 0.050 |
Why?
|
| Industry | 1 | 2002 | 17 | 0.050 |
Why?
|
| Amnesia | 1 | 2002 | 15 | 0.050 |
Why?
|
| Nervous System | 1 | 2002 | 89 | 0.050 |
Why?
|
| Acid-Base Equilibrium | 1 | 2002 | 33 | 0.050 |
Why?
|
| Hallucinations | 2 | 1995 | 29 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 1998 | 2754 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2001 | 83 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 1999 | 19 | 0.050 |
Why?
|
| Chest Pain | 1 | 2001 | 42 | 0.050 |
Why?
|
| Journalism | 1 | 2001 | 2 | 0.050 |
Why?
|
| Brain Death | 1 | 2002 | 82 | 0.050 |
Why?
|
| Protective Devices | 1 | 2001 | 8 | 0.050 |
Why?
|
| Aerosols | 1 | 2001 | 45 | 0.050 |
Why?
|
| Information Services | 1 | 2001 | 23 | 0.050 |
Why?
|
| Anesthetics, Inhalation | 1 | 2002 | 98 | 0.050 |
Why?
|
| Fatigue | 1 | 2001 | 179 | 0.050 |
Why?
|
| Critical Illness | 1 | 2023 | 306 | 0.050 |
Why?
|
| United States Occupational Safety and Health Administration | 1 | 2000 | 1 | 0.050 |
Why?
|
| Maximum Allowable Concentration | 1 | 2000 | 2 | 0.050 |
Why?
|
| Noise, Occupational | 1 | 2000 | 2 | 0.050 |
Why?
|
| Workers' Compensation | 1 | 2000 | 4 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2002 | 279 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2000 | 39 | 0.040 |
Why?
|
| Meclizine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Benztropine | 1 | 1999 | 4 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2000 | 50 | 0.040 |
Why?
|
| Radiography | 4 | 1990 | 809 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 1999 | 120 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 1991 | 240 | 0.040 |
Why?
|
| Regression Analysis | 4 | 1994 | 590 | 0.040 |
Why?
|
| Analgesia, Epidural | 1 | 1999 | 38 | 0.040 |
Why?
|
| Propranolol | 1 | 1999 | 44 | 0.040 |
Why?
|
| Potassium Permanganate | 1 | 1998 | 2 | 0.040 |
Why?
|
| Eye Burns | 1 | 1998 | 5 | 0.040 |
Why?
|
| Headache | 3 | 1988 | 72 | 0.040 |
Why?
|
| Polypharmacy | 1 | 1999 | 15 | 0.040 |
Why?
|
| Terbutaline | 1 | 1999 | 16 | 0.040 |
Why?
|
| Triazoles | 1 | 1999 | 102 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1999 | 105 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 1998 | 38 | 0.040 |
Why?
|
| Thumb | 1 | 1999 | 22 | 0.040 |
Why?
|
| Crystallization | 1 | 1999 | 210 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1999 | 72 | 0.040 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 1998 | 6 | 0.040 |
Why?
|
| Arm | 1 | 1999 | 97 | 0.040 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1998 | 14 | 0.040 |
Why?
|
| Sex Factors | 2 | 1994 | 1062 | 0.040 |
Why?
|
| Patient Transfer | 2 | 1996 | 94 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 1996 | 158 | 0.040 |
Why?
|
| Rewarming | 1 | 1997 | 5 | 0.040 |
Why?
|
| Smoke Inhalation Injury | 1 | 1997 | 7 | 0.040 |
Why?
|
| Cyclohexanols | 1 | 1997 | 7 | 0.040 |
Why?
|
| Heat Stress Disorders | 1 | 1997 | 12 | 0.040 |
Why?
|
| Toluidines | 1 | 1997 | 18 | 0.040 |
Why?
|
| Cosmetics | 1 | 1997 | 7 | 0.040 |
Why?
|
| Curriculum | 2 | 1992 | 567 | 0.040 |
Why?
|
| Triazines | 1 | 1997 | 53 | 0.040 |
Why?
|
| Household Articles | 1 | 1997 | 15 | 0.040 |
Why?
|
| Wounds and Injuries | 2 | 1990 | 259 | 0.040 |
Why?
|
| Chromatography, Gas | 1 | 1996 | 28 | 0.040 |
Why?
|
| Delayed-Action Preparations | 2 | 1994 | 110 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 1996 | 40 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1997 | 371 | 0.030 |
Why?
|
| Tachycardia, Ventricular | 1 | 1997 | 124 | 0.030 |
Why?
|
| Hospitals, Psychiatric | 1 | 1996 | 23 | 0.030 |
Why?
|
| Reference Standards | 1 | 1996 | 144 | 0.030 |
Why?
|
| Enzyme Multiplied Immunoassay Technique | 1 | 1995 | 1 | 0.030 |
Why?
|
| Codeine | 1 | 1995 | 12 | 0.030 |
Why?
|
| Hydromorphone | 1 | 1995 | 11 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 1995 | 63 | 0.030 |
Why?
|
| Materials Testing | 1 | 1996 | 93 | 0.030 |
Why?
|
| Pregnancy, Multiple | 1 | 1995 | 37 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 683 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1995 | 141 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1995 | 222 | 0.030 |
Why?
|
| Myoclonus | 1 | 1995 | 16 | 0.030 |
Why?
|
| Program Evaluation | 1 | 1997 | 307 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 1995 | 41 | 0.030 |
Why?
|
| Mass Screening | 1 | 2000 | 636 | 0.030 |
Why?
|
| Pyridines | 1 | 1997 | 315 | 0.030 |
Why?
|
| Ataxia | 1 | 1995 | 39 | 0.030 |
Why?
|
| Morphine | 1 | 1995 | 130 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1996 | 492 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 1995 | 1070 | 0.030 |
Why?
|
| Nausea | 1 | 1995 | 176 | 0.030 |
Why?
|
| Emergency Nursing | 1 | 1993 | 7 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 1992 | 94 | 0.030 |
Why?
|
| Memory | 1 | 1995 | 220 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 1993 | 112 | 0.030 |
Why?
|
| Waiting Lists | 1 | 1994 | 183 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1993 | 254 | 0.030 |
Why?
|
| Pharmacology | 1 | 1992 | 11 | 0.030 |
Why?
|
| Specialization | 1 | 1992 | 65 | 0.030 |
Why?
|
| Observation | 2 | 2002 | 38 | 0.030 |
Why?
|
| Certification | 1 | 1992 | 61 | 0.030 |
Why?
|
| Bacteremia | 1 | 1993 | 102 | 0.030 |
Why?
|
| Diazepam | 1 | 1992 | 27 | 0.030 |
Why?
|
| Pathology | 1 | 1992 | 32 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 2363 | 0.020 |
Why?
|
| Medicine | 1 | 1992 | 91 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1992 | 202 | 0.020 |
Why?
|
| Canada | 1 | 1992 | 208 | 0.020 |
Why?
|
| Cardiolipins | 1 | 1991 | 17 | 0.020 |
Why?
|
| Furosemide | 1 | 1991 | 34 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1764 | 0.020 |
Why?
|
| Drug Therapy | 1 | 1991 | 70 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1991 | 109 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 1990 | 45 | 0.020 |
Why?
|
| Tracheotomy | 1 | 1990 | 18 | 0.020 |
Why?
|
| Chronobiology Phenomena | 1 | 1990 | 4 | 0.020 |
Why?
|
| Alcoholism | 1 | 1992 | 178 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 1990 | 53 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1993 | 223 | 0.020 |
Why?
|
| Computer Simulation | 1 | 1994 | 1097 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 2659 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 1992 | 185 | 0.020 |
Why?
|
| Systole | 1 | 1990 | 115 | 0.020 |
Why?
|
| Diastole | 1 | 1990 | 141 | 0.020 |
Why?
|
| Thiocyanates | 1 | 1989 | 11 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1989 | 38 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1992 | 711 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 360 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 1992 | 385 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2008 | 18 | 0.020 |
Why?
|
| Chemistry, Analytic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1990 | 162 | 0.020 |
Why?
|
| Smoking | 3 | 1990 | 621 | 0.020 |
Why?
|
| Pain | 2 | 1988 | 400 | 0.020 |
Why?
|
| Safety | 2 | 2001 | 149 | 0.020 |
Why?
|
| Axillary Vein | 1 | 1988 | 5 | 0.020 |
Why?
|
| Acrylic Resins | 1 | 1988 | 22 | 0.020 |
Why?
|
| Digestive System | 1 | 1988 | 42 | 0.020 |
Why?
|
| Erythrocyte Count | 1 | 1988 | 22 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1991 | 1088 | 0.020 |
Why?
|
| Subclavian Vein | 1 | 1988 | 15 | 0.020 |
Why?
|
| Arteries | 1 | 1989 | 180 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1989 | 500 | 0.020 |
Why?
|
| Craniocerebral Trauma | 1 | 1988 | 56 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2007 | 20 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1988 | 64 | 0.020 |
Why?
|
| Privacy | 1 | 2007 | 20 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2007 | 47 | 0.020 |
Why?
|
| Chlorides | 1 | 1988 | 103 | 0.020 |
Why?
|
| Necrosis | 1 | 1988 | 209 | 0.020 |
Why?
|
| Fishes, Poisonous | 1 | 1987 | 2 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1991 | 681 | 0.020 |
Why?
|
| Povidone | 1 | 1987 | 6 | 0.020 |
Why?
|
| Povidone-Iodine | 1 | 1987 | 9 | 0.020 |
Why?
|
| Vehicle Emissions | 1 | 1986 | 3 | 0.020 |
Why?
|
| Length of Stay | 2 | 2002 | 733 | 0.020 |
Why?
|
| Models, Biological | 1 | 1994 | 1765 | 0.020 |
Why?
|
| Burns, Inhalation | 1 | 1986 | 4 | 0.020 |
Why?
|
| Iodine | 1 | 1987 | 43 | 0.020 |
Why?
|
| Triage | 1 | 2007 | 111 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2007 | 280 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1986 | 64 | 0.020 |
Why?
|
| Pressure Ulcer | 1 | 1987 | 42 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1986 | 59 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 146 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 1986 | 58 | 0.020 |
Why?
|
| Transportation of Patients | 1 | 1986 | 32 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1988 | 217 | 0.020 |
Why?
|
| Heart Rate | 1 | 1988 | 495 | 0.020 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2005 | 50 | 0.020 |
Why?
|
| Heating | 3 | 1990 | 14 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1986 | 260 | 0.010 |
Why?
|
| Lung | 1 | 1990 | 1259 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 427 | 0.010 |
Why?
|
| Alcohols | 1 | 2003 | 15 | 0.010 |
Why?
|
| Cyanides | 1 | 2003 | 16 | 0.010 |
Why?
|
| Tracheostomy | 1 | 2003 | 45 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 200 | 0.010 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 1 | 2002 | 2 | 0.010 |
Why?
|
| Tear Gases | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hemorrhagic Fevers, Viral | 1 | 2002 | 3 | 0.010 |
Why?
|
| Cholera | 1 | 2002 | 6 | 0.010 |
Why?
|
| Glanders | 1 | 2002 | 3 | 0.010 |
Why?
|
| Ricin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Smallpox | 1 | 2002 | 6 | 0.010 |
Why?
|
| Tularemia | 1 | 2002 | 8 | 0.010 |
Why?
|
| Q Fever | 1 | 2002 | 8 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2002 | 21 | 0.010 |
Why?
|
| T-2 Toxin | 1 | 2002 | 18 | 0.010 |
Why?
|
| Brucellosis | 1 | 2002 | 13 | 0.010 |
Why?
|
| Plague | 1 | 2002 | 27 | 0.010 |
Why?
|
| Medical Audit | 1 | 2001 | 39 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1999 | 19 | 0.010 |
Why?
|
| Algorithms | 1 | 1988 | 1876 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 461 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1999 | 245 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2001 | 202 | 0.010 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 1999 | 15 | 0.010 |
Why?
|
| Dobutamine | 1 | 1999 | 61 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 461 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1999 | 125 | 0.010 |
Why?
|
| Suburban Population | 1 | 1998 | 6 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 56 | 0.010 |
Why?
|
| Acetone | 1 | 1998 | 6 | 0.010 |
Why?
|
| Antiemetics | 1 | 1999 | 98 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1998 | 68 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 1999 | 89 | 0.010 |
Why?
|
| Lead | 1 | 1998 | 26 | 0.010 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 1997 | 4 | 0.010 |
Why?
|
| Piperazines | 1 | 1999 | 283 | 0.010 |
Why?
|
| Contraindications | 1 | 1997 | 70 | 0.010 |
Why?
|
| Dopamine | 1 | 1999 | 276 | 0.010 |
Why?
|
| Mice | 1 | 1991 | 11743 | 0.010 |
Why?
|
| Triplets | 1 | 1995 | 8 | 0.010 |
Why?
|
| Fluorescence Polarization | 1 | 1995 | 8 | 0.010 |
Why?
|
| Financial Management, Hospital | 1 | 1995 | 4 | 0.010 |
Why?
|
| Utilization Review | 1 | 1995 | 23 | 0.010 |
Why?
|
| Twins | 1 | 1995 | 65 | 0.010 |
Why?
|
| Quality Control | 1 | 1995 | 117 | 0.010 |
Why?
|
| Organizational Policy | 1 | 1995 | 55 | 0.010 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 1995 | 69 | 0.010 |
Why?
|
| Urban Population | 1 | 1995 | 224 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 1995 | 225 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 2014 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 1992 | 6 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1991 | 12 | 0.010 |
Why?
|
| Rheumatoid Factor | 1 | 1991 | 25 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 270 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1991 | 83 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1991 | 163 | 0.010 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1990 | 16 | 0.010 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1991 | 59 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 996 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 1991 | 159 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1991 | 231 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1990 | 160 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 1996 | 1044 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1991 | 465 | 0.010 |
Why?
|
| Fractures, Closed | 1 | 1988 | 9 | 0.000 |
Why?
|
| Sodium Hydroxide | 1 | 1988 | 5 | 0.000 |
Why?
|
| Streptokinase | 1 | 1988 | 12 | 0.000 |
Why?
|
| Physical Exertion | 1 | 1988 | 38 | 0.000 |
Why?
|
| Nursing Staff, Hospital | 1 | 1988 | 42 | 0.000 |
Why?
|
| Joint Dislocations | 1 | 1988 | 27 | 0.000 |
Why?
|
| ROC Curve | 1 | 1990 | 781 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 312 | 0.000 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1988 | 51 | 0.000 |
Why?
|
| Gastric Mucosa | 1 | 1988 | 66 | 0.000 |
Why?
|
| Warfarin | 1 | 1988 | 104 | 0.000 |
Why?
|
| Syndrome | 1 | 1988 | 449 | 0.000 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1988 | 111 | 0.000 |
Why?
|
| Risk | 1 | 1987 | 657 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 1151 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1987 | 1721 | 0.000 |
Why?
|
| Rats | 1 | 1988 | 4041 | 0.000 |
Why?
|
| Internship and Residency | 1 | 1988 | 1043 | 0.000 |
Why?
|